Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 210

Sort by

Sort Order Select

Journal Articles

A novel intercontinental external quality assessment program for flow cytometric measurable residual disease assessment in pediatric AML

Blood (2025) 146 (Supplement 1): 3514.

https://doi.org/10.1182/blood-2025-3514

Published: 2025

Journal Articles

KMT2A::AF6 fusion protein localizes to PML nuclear bodies and undergoes ATO-induced degradation: A potential novel therapeutic approach for KMT2A::AF6-rearranged Acute Myeloid Leukemia

Claudia Tregnago, Sara Perpinello, Ambra Da Ros, Maddalena Benetton, Giorgia Longo, Helmut Hanenberg, Jan-Henning Klusmann, Dirk Reinhardt, Franco Locatelli, Martina Pigazzi

Blood (2025) 146 (Supplement 1): 753.

https://doi.org/10.1182/blood-2025-753

Published: 2025

Journal Articles

ITCC-101/APAL2020D: A randomized Phase 3 trial of fludarabine/cytarabine/gemtuzumab ozogamycin with or without venetoclax in children with relapsed Acute Myeloid Leukemia

Blood (2025) 146 (Supplement 1): 1656.

https://doi.org/10.1182/blood-2025-1656

Published: 2025

Journal Articles

Central nervous system involvement in pediatric Acute Myeloid Leukemia: A comprehensive report from the AML-BFM group

Katje Kleyer, Michael Schuendeln, Stephanie Sendker, Lina Marie Hoffmeister, Markus Schneider, Nils Von Neuhoff, Jan-Henning Klusmann, Dirk Reinhardt, Evangelia Antoniou

Blood (2025) 146 (Supplement 1): 3403.

https://doi.org/10.1182/blood-2025-3403

Published: 2025

Journal Articles

Characterization of children and adolescents with Acute Myeloid Leukemia potentially treatable with menin inhibitors

Dirk Reinhardt, Lina Marie Hoffmeister, Markus Schneider, Jan-Henning Klusmann, Lisa Ostermann, Tabea Ziedrich, Kristian Juul-Dam, Nils Von Neuhoff, Caroline Augsburg, Denise Kondryn, Christel Katerkamp, Sophia Meerkamp, Naghmeh Niktoreh, Evangelia Antoniou, Helena Kerp, Katarzyna Majstrowicz, Katharina Waack

Blood (2025) 146 (Supplement 1): 5174.

https://doi.org/10.1182/blood-2025-5174

Published: 2025

Journal Articles

Clinical, cytogenetic and molecular characteriszation of Mecom- rearranged pediatric de novo Acute Myeloid Leukemia (AML): A retrospective cohort study of the international-berlin-frankfurt-Münster (I-BFM) AML-study group

Blood (2025) 146 (Supplement 1): 1608.

https://doi.org/10.1182/blood-2025-1608

Published: 2025

Journal Articles

TP53 mutations define a high-risk subgroup in pediatric Acute Myeloid Leukemia with distinct molecular and cytogenetic features

Stephanie Sendker, Lina Marie Hoffmeister, Nils Von Neuhoff, Jan-Henning Klusmann, Dirk Reinhardt, Markus Schneider, Evangelia Antoniou

Blood (2025) 146 (Supplement 1): 447.

https://doi.org/10.1182/blood-2025-447

Published: 2025

Journal Articles

CPX-351 in Down syndrome-associated Myeloid Leukemia: Results and Prognostic Factors from the Phase 3 ML-DS 2018 Trial

Blood blood.2025030775.

https://doi.org/10.1182/blood.2025030775

Published: 2025

Includes: Supplemental data

Journal Articles

Diagnosis and Management of AML in Pediatric Patients: Consensus Recommendations from an International Expert Panel

Blood blood.2024027904.

https://doi.org/10.1182/blood.2024027904

Published: 2025

Includes: Supplemental data

Journal Articles

Comprehensive Analysis of Target and Immune Checkpoint Markers in Pediatric AML

Stephanie Sendker, Jens Gehlen, Tabea Ziedrich, Evangelia Antoniou, Markus Schneider, Nils Von Neuhoff, Dirk Reinhardt, Lina Marie Hoffmeister

Blood (2024) 144 (Supplement 1): 4322.

https://doi.org/10.1182/blood-2024-208614

Published: 2024

Journal Articles

Addition of Anti-T-Lymphocyte-Globuline As Graft Versus Host Disease Prophylaxis for Matched Unrelated Donors Equalizes Outcomes with Matched Sibling Donors: Results from the AML SCT-BFM 2007 Trial

Blood (2024) 144 (Supplement 1): 3563.

https://doi.org/10.1182/blood-2024-200574

Published: 2024

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Acute Myeloid Leukemia: Results of the AML BFM Study Group

Eva Rettinger, Martin Hutter, Birte Karschen, Evangelia Antoniou, Peter Bader, Rita Beier, Birgit Burkhardt, Ursula Creutzig, Gabriele Escherich, Jan-Henning Klusmann, Peter Lang, Naghmeh Niktoreh, Martin G. Sauer, Stephanie Sendker, Dirk Reinhardt, Katharina Waack

Blood (2024) 144 (Supplement 1): 3548.

https://doi.org/10.1182/blood-2024-208311

Published: 2024

Journal Articles

Significance of RT-qPCR-Based Measurable Residual Disease for Optimizing the Treatment of Pediatric Acute Myeloid Leukemia

Evangelia Antoniou, Lina Marie Hoffmeister, Nils Von Neuhoff, Dirk Reinhardt, Markus Schneider, Stephanie Sendker

Blood (2024) 144 (Supplement 1): 228.

https://doi.org/10.1182/blood-2024-208718

Published: 2024

Journal Articles

Independent, International Validation and Refinement of a Machine Learning Algorithm to Classify Acute Leukemia Using Routine Laboratory Features

Amin T. Turki, Alberto Hernández Sánchez, Wellington Silva, Magdalena Karasek, Luca Guarnera, Koray Yalçin, Amir Enshaei, Marta Sobas, Dirk Reinhardt, Maria M Rivas, Deepak Kumar Mishra, Eduardo Rego, Ahmet Koc, Paola Núñez Medina, Maria Teresa Voso, Anthony Moorman, Felix Nensa, Merlin Engelke

Blood (2024) 144 (Supplement 1): 790.

https://doi.org/10.1182/blood-2024-207058

Published: 2024

Journal Articles

Treatment of Molecular Relapses in Pediatric AML Saves Toxicities Prior to Hematopoietic Stem Cell Transplantation (HSCT) - Results of AMoRe2017 Trial

Amelie Polutta, Dirk Reinhardt, Andre Baruchel, Henrik Hasle, Franco Locatelli, C. Michel Zwaan, Michael Frühwald, Silke Westphal, Michael Dworzak, Heidrun Boztug, Gabriele Escherich, Thomas Lehrnbecher, Bianca F. Goemans, Brigitte Strahm, Markus Schneider, Lina Hoffmeister, Katharina Waack

Blood (2023) 142 (Supplement 1): 1521.

https://doi.org/10.1182/blood-2023-180820

Published: 2023

Journal Articles

Europeanpediatric Acute Leukemia (EuPAL) Registry

Katarzyna Majstrowicz, Katharina Waack, Evangelia Antoniou, Naghmeh Niktoreh, Gwen Nichols, Laura Di Laurenzio, Michele S. Redell, Todd Cooper, E. Anders Kolb, Sarah K. Tasian, Franco Locatelli, C. Michel Zwaan, Dirk Reinhardt

Blood (2023) 142 (Supplement 1): 1496.

https://doi.org/10.1182/blood-2023-189684

Published: 2023

Journal Articles

Characteristics of FLT3 -ITD and Efficacy of Sorafenib Treatment in Pediatric AML: A Report from AML-BFM Study Group

Evangelia Antoniou, Annika Puschnig, Lina Marie Hoffmeister, Amani Awada, Nils Von Neuhoff, Markus Schneider, Dirk Reinhardt, Naghmeh Niktoreh

Blood (2023) 142 (Supplement 1): 4217.

https://doi.org/10.1182/blood-2023-187465

Published: 2023

Journal Articles

APAL2020SC Pediatric Acute Leukemia (PedAL) Screening Trial - Developing New Therapies for Relapsed Leukemias

Michele S. Redell, Todd A. Alonzo, Robert Gerbing, Jim Wang, Maureen M. O'Brien, Gwen Nichols, Laura Di Laurenzio, Sarah K. Tasian, C. Michel Zwaan, Dirk Reinhardt, E. Anders Kolb, Todd Cooper

Blood (2023) 142 (Supplement 1): 1492.

https://doi.org/10.1182/blood-2023-190947

Published: 2023

Journal Articles

Machine Learning Provides Individualized Prediction of Outcomes after First Complete Remission in Adult AML Patients - Results from the Harmony Platform

Blood (2023) 142 (Supplement 1): 62.

https://doi.org/10.1182/blood-2023-183029

Published: 2023

Journal Articles

Impact-AML: A European Master Framework for Cohort Studies and Pragmatic Clinical Trials in Relapse or Refractory Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 1533.

https://doi.org/10.1182/blood-2023-184745

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

A novel intercontinental external quality assessment program for flow cytometric measurable residual disease assessment in pediatric AML

KMT2A::AF6 fusion protein localizes to PML nuclear bodies and undergoes ATO-induced degradation: A potential novel therapeutic approach for KMT2A::AF6-rearranged Acute Myeloid Leukemia

ITCC-101/APAL2020D: A randomized Phase 3 trial of fludarabine/cytarabine/gemtuzumab ozogamycin with or without venetoclax in children with relapsed Acute Myeloid Leukemia

Central nervous system involvement in pediatric Acute Myeloid Leukemia: A comprehensive report from the AML-BFM group

Characterization of children and adolescents with Acute Myeloid Leukemia potentially treatable with menin inhibitors

Clinical, cytogenetic and molecular characteriszation of Mecom- rearranged pediatric de novo Acute Myeloid Leukemia (AML): A retrospective cohort study of the international-berlin-frankfurt-Münster (I-BFM) AML-study group

TP53 mutations define a high-risk subgroup in pediatric Acute Myeloid Leukemia with distinct molecular and cytogenetic features

CPX-351 in Down syndrome-associated Myeloid Leukemia: Results and Prognostic Factors from the Phase 3 ML-DS 2018 Trial

Diagnosis and Management of AML in Pediatric Patients: Consensus Recommendations from an International Expert Panel

Comprehensive Analysis of Target and Immune Checkpoint Markers in Pediatric AML

Addition of Anti-T-Lymphocyte-Globuline As Graft Versus Host Disease Prophylaxis for Matched Unrelated Donors Equalizes Outcomes with Matched Sibling Donors: Results from the AML SCT-BFM 2007 Trial

Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Acute Myeloid Leukemia: Results of the AML BFM Study Group

Significance of RT-qPCR-Based Measurable Residual Disease for Optimizing the Treatment of Pediatric Acute Myeloid Leukemia

Independent, International Validation and Refinement of a Machine Learning Algorithm to Classify Acute Leukemia Using Routine Laboratory Features

Treatment of Molecular Relapses in Pediatric AML Saves Toxicities Prior to Hematopoietic Stem Cell Transplantation (HSCT) - Results of AMoRe2017 Trial

Europeanpediatric Acute Leukemia (EuPAL) Registry

Characteristics of FLT3 -ITD and Efficacy of Sorafenib Treatment in Pediatric AML: A Report from AML-BFM Study Group

APAL2020SC Pediatric Acute Leukemia (PedAL) Screening Trial - Developing New Therapies for Relapsed Leukemias

Machine Learning Provides Individualized Prediction of Outcomes after First Complete Remission in Adult AML Patients - Results from the Harmony Platform

Impact-AML: A European Master Framework for Cohort Studies and Pragmatic Clinical Trials in Relapse or Refractory Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only